These include azacitidine plus an IDH inhibitor for IDH-mutated AML in older or less-fit patients, midostaurin plus 7 + 3 in fit FLT3-mutated AML, or consideration of FLT3 inhibitors in combination with azacitidine in older or less-fit FLT3-mutated AML patients3. Here, FLT3 is linked to acute myeloid leukemia.